COMPOSITIONS OF LONG-TERM ACTION INSULINS

FIELD: pharmacology.SUBSTANCE: group of inventions refers to an aqueous pharmaceutical composition containing 270-330 U/ml of glargine insulin [equimolar to 270-330 IU of human insulin], wherein the composition containing 300 U/ml of glargine insulin is excluded, for treatment of type I and II diabe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: FRIK Annke, FYURST Kristiane, TERCH Katrin, BEKKER Rajnkhard, MYULLER Verner, SHETTLE Izabell, LOOS Petra, BODERKE Peter, VERNER Ulrikh
Format: Patent
Sprache:eng ; rus
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator FRIK Annke
FYURST Kristiane
TERCH Katrin
BEKKER Rajnkhard
MYULLER Verner
SHETTLE Izabell
LOOS Petra
BODERKE Peter
VERNER Ulrikh
description FIELD: pharmacology.SUBSTANCE: group of inventions refers to an aqueous pharmaceutical composition containing 270-330 U/ml of glargine insulin [equimolar to 270-330 IU of human insulin], wherein the composition containing 300 U/ml of glargine insulin is excluded, for treatment of type I and II diabetes.EFFECT: application of these inventions allows to provide a basal insulin reserve within 24 hours after a subcutaneous injection of a single dose.16 cl, 9 dwg, 12 tbl, 18 ex Группа изобретений относится к фармацевтической композиции на водной основе, содержащей 270-330 Ед/мл инсулина гларгина [эквимолярно 270-330 МЕ инсулина человека], где композиция, содержащая 300 Ед/мл инсулина гларгина, исключена, для лечения диабета I и II типа. Использование данных изобретений позволяет обеспечить запас базального инсулина в течение 24 часов после подкожной инъекции однократной дозы. 2 н. и 14 з.п. ф-лы, 9 ил., 12 табл., 18 пр.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_RU2642662C2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>RU2642662C2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_RU2642662C23</originalsourceid><addsrcrecordid>eNrjZNB09vcN8A_2DPH09wtW8HdT8PH3c9cNcQ3yVXB0BgkqePoFh_oACR4G1rTEnOJUXijNzaDg5hri7KGbWpAfn1pckJicmpdaEh8UamRmYmRmZuRsZEyEEgAEnyRe</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>COMPOSITIONS OF LONG-TERM ACTION INSULINS</title><source>esp@cenet</source><creator>FRIK Annke ; FYURST Kristiane ; TERCH Katrin ; BEKKER Rajnkhard ; MYULLER Verner ; SHETTLE Izabell ; LOOS Petra ; BODERKE Peter ; VERNER Ulrikh</creator><creatorcontrib>FRIK Annke ; FYURST Kristiane ; TERCH Katrin ; BEKKER Rajnkhard ; MYULLER Verner ; SHETTLE Izabell ; LOOS Petra ; BODERKE Peter ; VERNER Ulrikh</creatorcontrib><description>FIELD: pharmacology.SUBSTANCE: group of inventions refers to an aqueous pharmaceutical composition containing 270-330 U/ml of glargine insulin [equimolar to 270-330 IU of human insulin], wherein the composition containing 300 U/ml of glargine insulin is excluded, for treatment of type I and II diabetes.EFFECT: application of these inventions allows to provide a basal insulin reserve within 24 hours after a subcutaneous injection of a single dose.16 cl, 9 dwg, 12 tbl, 18 ex Группа изобретений относится к фармацевтической композиции на водной основе, содержащей 270-330 Ед/мл инсулина гларгина [эквимолярно 270-330 МЕ инсулина человека], где композиция, содержащая 300 Ед/мл инсулина гларгина, исключена, для лечения диабета I и II типа. Использование данных изобретений позволяет обеспечить запас базального инсулина в течение 24 часов после подкожной инъекции однократной дозы. 2 н. и 14 з.п. ф-лы, 9 ил., 12 табл., 18 пр.</description><language>eng ; rus</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2018</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20180125&amp;DB=EPODOC&amp;CC=RU&amp;NR=2642662C2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76516</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20180125&amp;DB=EPODOC&amp;CC=RU&amp;NR=2642662C2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>FRIK Annke</creatorcontrib><creatorcontrib>FYURST Kristiane</creatorcontrib><creatorcontrib>TERCH Katrin</creatorcontrib><creatorcontrib>BEKKER Rajnkhard</creatorcontrib><creatorcontrib>MYULLER Verner</creatorcontrib><creatorcontrib>SHETTLE Izabell</creatorcontrib><creatorcontrib>LOOS Petra</creatorcontrib><creatorcontrib>BODERKE Peter</creatorcontrib><creatorcontrib>VERNER Ulrikh</creatorcontrib><title>COMPOSITIONS OF LONG-TERM ACTION INSULINS</title><description>FIELD: pharmacology.SUBSTANCE: group of inventions refers to an aqueous pharmaceutical composition containing 270-330 U/ml of glargine insulin [equimolar to 270-330 IU of human insulin], wherein the composition containing 300 U/ml of glargine insulin is excluded, for treatment of type I and II diabetes.EFFECT: application of these inventions allows to provide a basal insulin reserve within 24 hours after a subcutaneous injection of a single dose.16 cl, 9 dwg, 12 tbl, 18 ex Группа изобретений относится к фармацевтической композиции на водной основе, содержащей 270-330 Ед/мл инсулина гларгина [эквимолярно 270-330 МЕ инсулина человека], где композиция, содержащая 300 Ед/мл инсулина гларгина, исключена, для лечения диабета I и II типа. Использование данных изобретений позволяет обеспечить запас базального инсулина в течение 24 часов после подкожной инъекции однократной дозы. 2 н. и 14 з.п. ф-лы, 9 ил., 12 табл., 18 пр.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2018</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNB09vcN8A_2DPH09wtW8HdT8PH3c9cNcQ3yVXB0BgkqePoFh_oACR4G1rTEnOJUXijNzaDg5hri7KGbWpAfn1pckJicmpdaEh8UamRmYmRmZuRsZEyEEgAEnyRe</recordid><startdate>20180125</startdate><enddate>20180125</enddate><creator>FRIK Annke</creator><creator>FYURST Kristiane</creator><creator>TERCH Katrin</creator><creator>BEKKER Rajnkhard</creator><creator>MYULLER Verner</creator><creator>SHETTLE Izabell</creator><creator>LOOS Petra</creator><creator>BODERKE Peter</creator><creator>VERNER Ulrikh</creator><scope>EVB</scope></search><sort><creationdate>20180125</creationdate><title>COMPOSITIONS OF LONG-TERM ACTION INSULINS</title><author>FRIK Annke ; FYURST Kristiane ; TERCH Katrin ; BEKKER Rajnkhard ; MYULLER Verner ; SHETTLE Izabell ; LOOS Petra ; BODERKE Peter ; VERNER Ulrikh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_RU2642662C23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; rus</language><creationdate>2018</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>FRIK Annke</creatorcontrib><creatorcontrib>FYURST Kristiane</creatorcontrib><creatorcontrib>TERCH Katrin</creatorcontrib><creatorcontrib>BEKKER Rajnkhard</creatorcontrib><creatorcontrib>MYULLER Verner</creatorcontrib><creatorcontrib>SHETTLE Izabell</creatorcontrib><creatorcontrib>LOOS Petra</creatorcontrib><creatorcontrib>BODERKE Peter</creatorcontrib><creatorcontrib>VERNER Ulrikh</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>FRIK Annke</au><au>FYURST Kristiane</au><au>TERCH Katrin</au><au>BEKKER Rajnkhard</au><au>MYULLER Verner</au><au>SHETTLE Izabell</au><au>LOOS Petra</au><au>BODERKE Peter</au><au>VERNER Ulrikh</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>COMPOSITIONS OF LONG-TERM ACTION INSULINS</title><date>2018-01-25</date><risdate>2018</risdate><abstract>FIELD: pharmacology.SUBSTANCE: group of inventions refers to an aqueous pharmaceutical composition containing 270-330 U/ml of glargine insulin [equimolar to 270-330 IU of human insulin], wherein the composition containing 300 U/ml of glargine insulin is excluded, for treatment of type I and II diabetes.EFFECT: application of these inventions allows to provide a basal insulin reserve within 24 hours after a subcutaneous injection of a single dose.16 cl, 9 dwg, 12 tbl, 18 ex Группа изобретений относится к фармацевтической композиции на водной основе, содержащей 270-330 Ед/мл инсулина гларгина [эквимолярно 270-330 МЕ инсулина человека], где композиция, содержащая 300 Ед/мл инсулина гларгина, исключена, для лечения диабета I и II типа. Использование данных изобретений позволяет обеспечить запас базального инсулина в течение 24 часов после подкожной инъекции однократной дозы. 2 н. и 14 з.п. ф-лы, 9 ил., 12 табл., 18 пр.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; rus
recordid cdi_epo_espacenet_RU2642662C2
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title COMPOSITIONS OF LONG-TERM ACTION INSULINS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-17T08%3A04%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=FRIK%20Annke&rft.date=2018-01-25&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ERU2642662C2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true